0.0865
4.95%
-0.0045
After Hours:
.0865
Novabay Pharmaceuticals Inc stock is currently priced at $0.0865, with a 24-hour trading volume of 15.08M.
It has seen a -4.95% decreased in the last 24 hours and a -14.44% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.0918 pivot point. If it approaches the $0.0821 support level, significant changes may occur.
Previous Close:
$0.091
Open:
$0.0915
24h Volume:
15.08M
Market Cap:
$3.12M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.00826
EPS:
-10.47
Net Cash Flow:
$-5.04M
1W Performance:
+7.05%
1M Performance:
-14.44%
6M Performance:
-74.93%
1Y Performance:
-91.08%
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
Nov-15-17 | Reiterated | Laidlaw | Buy |
Jun-05-17 | Initiated | ROTH Capital | Buy |
Mar-27-17 | Initiated | Laidlaw | Buy |
Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
Dec-14-15 | Reiterated | Maxim Group | Buy |
Apr-30-15 | Resumed | Maxim Group | Buy |
Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
NioBay annonce la clôture de la première tranche d’un placement privé
GlobeNewswire Inc.
NioBay intercepte des teneurs historiques sur son projet Crevier et confirme le prolongement de la zone minéralisée
GlobeNewswire Inc.
NioBay Metals closes option agreement to acquire Foothills property
GlobeNewswire Inc.
Les Métaux NioBay signe une convention d'option afin de mettre la main sur des propriétés à fort potentiel en titane et phosphate
GlobeNewswire Inc.
Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Benzinga
Corporate Update on NioBay Activities
GlobeNewswire Inc.
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Novabay Pharmaceuticals Inc (NBY) Revenue 2024
NBY reported a revenue (TTM) of $14.64 million for the quarter ending September 30, 2023, a +5.08% rise year-over-year.
Novabay Pharmaceuticals Inc (NBY) Net Income 2024
NBY net income (TTM) was -$13.74 million for the quarter ending September 30, 2023, a -436.64% decrease year-over-year.
Novabay Pharmaceuticals Inc (NBY) Cash Flow 2024
NBY recorded a free cash flow (TTM) of -$5.04 million for the quarter ending September 30, 2023, a +48.97% increase year-over-year.
Novabay Pharmaceuticals Inc (NBY) Earnings per Share 2024
NBY earnings per share (TTM) was -$7.27 for the quarter ending September 30, 2023, a -24.70% decline year-over-year.
About Novabay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Cap:
|
Volume (24h):